Intellia Therapeutics Inc (NTLA) is near the top in its industry group according to InvestorsObserver. NTLA gets an overall rating of 61. That means it scores higher than 61 percent of stocks. Intellia Therapeutics Inc gets a 75 rank in the Biotechnology industry. Biotechnology is number 32 out of 148 industries.
What do These Ratings Mean?
Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.
Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.
What's Happening With Intellia Therapeutics Inc Stock Today?
Intellia Therapeutics Inc (NTLA) stock is lower by -9.74% while the S&P 500 has gained 0.22% as of 3:03 PM on Thursday, Jan 21. NTLA has fallen -$7.85 from the previous closing price of $80.56 on volume of 1,686,398 shares. Over the past year the S&P 500 is up 16.22% while NTLA has gained 396.65%. NTLA lost -$2.28 per share the over the last 12 months.
Click Here to get the full Stock Score Report on Intellia Therapeutics Inc (NTLA) Stock.
